7 terminated, 1 completed, 1 withdrawn. 7 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 6, Completed 1 |
| Phase 3 | 3 | Terminated 2, Withdrawn 1 |
Follow Radius Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome RAD011 - Prader-Willi Syndrome | Phase 3 | Withdrawn | Radius Pharmaceuticals, Inc. | 2023-01-01 | 2022-10-06 | |
| A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome RAD011, Placebo - Prader-Willi Syndrome | Phase 2 / Phase 3 | Terminated | Radius Pharmaceuticals, Inc. | 4 | 2022-04-13 | 2023-10-19 |
| A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome Cannabidiol Oral Solution - Prader-Willi Syndrome | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 2 | 2018-09-06 | 2023-06-22 |
| A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms Cannabidiol Oral Solution, Placebo, Vigabatrin - Infantile Spasm | Phase 3 | Terminated | Radius Pharmaceuticals, Inc. | 2 | 2018-09-05 | 2023-06-07 |
| Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome Cannabidiol, Placebo - Prader-Willi Syndrome | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 7 | 2018-05-09 | 2023-08-01 |
| Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures Cannabidiol Oral Solution - Childhood Absence Epilepsy | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 11 | 2018-02-20 | 2023-06-18 |
| Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures Cannabidiol Oral Solution - Childhood Absence Epilepsy | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 20 | 2017-12-29 | 2023-07-21 |
| Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms RAD1901, Placebo - Vasomotor Symptoms, Hot Flashes | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 139 | 2015-12-01 | 2019-03-13 |
| A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women RAD1901, Placebo - Hot Flashes | Phase 2 | Completed | Radius Pharmaceuticals, Inc. | 100 | 2009-03-01 | 2018-09-26 |
Prader-Willi Syndrome (4) · Epilepsy, Absence (2) · Hot Flashes (2) · Spasms, Infantile (1)
Cannabidiol (5) · RAD1901 (2) · Vigabatrin (1) · elacestrant (1)
United States (8)